Abstract：ObjectiveTo investigate the efficacy of Irbesartan combined with Huangkui Capsule in the treatment of chronic glomerulonephritis.MethodsFrom January 2016 to January 2017,40 patients with chronic glomerulonephritis treated in our hospital were selected as objects.According to the different therapeutic methods,they were divided into control group and observation group,20 cases in esch group.In the control group,patients were treated with Irbesartan only,while in the observation group,Huangkui Capsule was added.The clinical efficacy in the two groups was compared.ResultsBefore treatment,there was no significant difference in 24-hour proteinuria or serum creatinine(P＞0.05).After treatment,in the observation group[(0.82±0.24)g,(80.01±8.03)μmol/L]were lower than the observation group[(1.02±0.32)g,(83.52±10.11)μmol/L],and the differences were statistically significant(P＜0.05).After treatment,the 24-hour proteinuria and serum creatinine levels were lower than before treatment,and the differences were statistically significant(P＜0.05).The total effective treatment rate in the observation group (90.0%)was higher than that in the control group(70.0%),and the difference was statistically significant(P＜0.05).There was no significant difference in adverse reactions between the two groups (P＞0.05).ConclusionIrbesartan combined with Huangkui Capsule can obtain a great effect on treating chronic glomerulonephritis,which is worthy of clinical application and promotion.
京公网安备 11010502046607号